Influence of Sugar-Sweetened Beverages Intake on Sarcopenic Obesity, Visceral Obesity, and Sarcopenia in Lebanese Patients with MASLD: A Case-Control Study
- PMID: 38470703
- PMCID: PMC10931226
- DOI: 10.3390/healthcare12050591
Influence of Sugar-Sweetened Beverages Intake on Sarcopenic Obesity, Visceral Obesity, and Sarcopenia in Lebanese Patients with MASLD: A Case-Control Study
Abstract
Chronic liver diseases are a major global health concern.
Aims: this study investigated the links between medical, clinical, anthropometric, and dietary factors with dysfunction-associated steatotic liver disease (MASLD) in the Lebanese population using a case-control approach to uncover factors influencing visceral obesity, sarcopenia, and sarcopenic obesity.
Methods and materials: a total of 120 participants (20-70 years old) were divided into case and control groups based on liver disease diagnosis. Patient information was gathered through a questionnaire encompassing demographics, medical history, and beverage consumption. Anthropometric and body composition data were collected in a clinical setting.
Results: our findings indicated a clear association between the presence of MASLD and obesity, hypertension, and diabetes. The positive association with higher body mass index and all three conditions remained consistent even when data was stratified by case and control groups. A greater proportion of MASLD patients exhibited sarcopenic obesity. Furthermore, MASLD cases showed higher consumption of sugary beverages and a reduced intake of milk and water in their diets.
Conclusions: this study shed light on the health attributes and diets of the Lebanese population with liver diseases and suggested more research in this area and in a more ethnically diverse population.
Keywords: Lebanon; dysfunction-associated steatotic liver disease; nutrition; sarcopenia; sarcopenic obesity; sugar-sweetened beverages; visceral obesity.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
A cross-sectional study of risk factors associated with sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease.Front Med (Lausanne). 2025 Feb 18;12:1488068. doi: 10.3389/fmed.2025.1488068. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40041458 Free PMC article.
-
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.Cureus. 2023 Oct 17;15(10):e47240. doi: 10.7759/cureus.47240. eCollection 2023 Oct. Cureus. 2023. PMID: 38021965 Free PMC article.
-
Changing beverage consumption patterns have resulted in fewer liquid calories in the diets of US children: National Health and Nutrition Examination Survey 2001-2010.J Acad Nutr Diet. 2015 Apr;115(4):559-66.e4. doi: 10.1016/j.jand.2014.09.004. Epub 2014 Nov 7. J Acad Nutr Diet. 2015. PMID: 25441966
-
Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Nutrients. 2024 Feb 26;16(5):658. doi: 10.3390/nu16050658. Nutrients. 2024. PMID: 38474786 Free PMC article. Review.
-
Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis.J Clin Transl Hepatol. 2024 Mar 28;12(3):278-286. doi: 10.14218/JCTH.2023.00207. Epub 2024 Jan 26. J Clin Transl Hepatol. 2024. PMID: 38426198 Free PMC article. Review.
Cited by
-
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass.World J Gastroenterol. 2025 May 28;31(20):105346. doi: 10.3748/wjg.v31.i20.105346. World J Gastroenterol. 2025. PMID: 40495947 Free PMC article.
References
-
- Centers for Disease Control and Prevention Mortality in the United States. [(accessed on 7 May 2022)];2021 Available online: https://www.cdc.gov/nchs/products/databriefs/db456.htm.
LinkOut - more resources
Full Text Sources